Taiwan Aesthetics and dermatology companies and pipeline landscape (November 2026) | Drugnews
At least 5 Taiwanese biotech companies are active in Aesthetics and dermatology, with 6 assets in development or on the market. The most advanced is Caliway (6919)’s CBL-514 (Phase 3; Large-area abdominal fat reduction). Data as of 2026-11-01; updated as new information becomes available.
Taiwan pipelines
6 / 6
| Caliway (6919) | 6919 | CBL-514 | Not disclosed | Phase 3; first participant dosed | Large-area abdominal fat reduction | Not disclosed | 2026-09-23 | 2026-09-23 |
| Oneness Biotech (4743) | 4743 | FB825 | Not disclosed | Phase 2; recruiting | Atopic Dermatitis | Not disclosed | No dated update | 2026-06-15 |
| Caliway (6919) | 6919 | CBL-514 + tirzepatide | Not disclosed | Phase 2 IND authorized | Abdominal subcutaneous fat reduction in overweight or obese adults | Not disclosed | 2026-08-24 | 2026-08-24 |
| LIBO (7888) | 7888 | LIB-101 | Recombinant IL-12 glycoprotein | Phase 2a completed | Cutaneous T-cell lymphoma | Not disclosed | No dated update | 2026-05-25 2026-05-25 2026-05-25 |
| PharmaEssentia (6446) | 6446 | KX01 | Not disclosed | Phase 1; completed | Psoriasis | Not disclosed | No dated update | 2025-07-02 |
| Orient EuroPharma (4120) | 4120 | 未公開代號（嚴重痤瘡口服藥） | Not disclosed | Preparing marketing authorization application documents | Severe acne | Not disclosed | No dated update | 2026-03-31 |
No matches. Clear the search to show all rows.
Recent events
- CBL-514 global Phase 3 SUPREME-01 first participant dosed announced (company disclosure) Source
- CBL-514 Phase 2 study in Dercum's disease met its primary efficacy endpoint (company disclosure) Source
- CBL-514 plus tirzepatide Phase 2 IND authorized by FDA (company disclosure) Source
- LIB-101 emergency-radiation research collaboration with Fukushima Medical University (company disclosure) Source
Related Drugnews analysis
FAQ
Which Taiwanese companies are developing Aesthetics and dermatology?
Currently, 5 companies are included: Caliway (6919), Oneness Biotech (4743), LIBO (7888), PharmaEssentia (6446), Orient EuroPharma (4120). Their drugs, stages and indications are in the pipeline table above.
Which Taiwan-listed stocks are linked to Aesthetics and dermatology?
Taiwan-listed companies directly involved in Aesthetics and dermatology R&D, manufacturing or licensing include: Caliway (6919), Oneness Biotech (4743), LIBO (7888), PharmaEssentia (6446), Orient EuroPharma (4120). Compiled from public information; this is not investment advice.
Which Taiwanese Aesthetics and dermatology program is most advanced?
Caliway (6919)’s CBL-514 is at Phase 3 (Large-area abdominal fat reduction).
What is the latest important development in Taiwan’s Aesthetics and dermatology sector?
The latest record is 2026-09-23: Caliway (6919) CBL-514 global Phase 3 SUPREME-01 first participant dosed announced (company disclosure).
SourceHow often is this data updated?
Data as of 2026-11-01; updated when companies announce new developments or clinical progress. Every entry includes its original source and date.